BIND, Amgen Ink $180.5M Nanomedicine Partnership

BIND Biosciences Inc., of Cambridge, Mass., signed a deal with Amgen Inc., of Thousand Oaks, Calif., worth up to $180.5 million. to collaborate on development of a nanotechnology-based therapeutic for solid tumors.